(Total Views: 552)
Posted On: 12/11/2022 1:19:48 PM
Post# of 148878
Figgs: I agree that $10-12 would represent a fair discounted present value BO price based on an objective consideration of the two overriding, undeniable, and competing facts beyond change that should prove outcome determinative to any BO negotiation:
FDA documented hostility to Leronlimab approval vs Leronlimab's
documented potential to become the world's top revenue drug within 3-4
years of FDA approval.
What may be very difficult for new CYDY management to accomplish with the FDA may be considerably easier to accomplish for any well connected BP.
FDA documented hostility to Leronlimab approval vs Leronlimab's
documented potential to become the world's top revenue drug within 3-4
years of FDA approval.
What may be very difficult for new CYDY management to accomplish with the FDA may be considerably easier to accomplish for any well connected BP.
(5)
(0)Scroll down for more posts ▼
